22 research outputs found

    Measuring the Higgs Sector

    Full text link
    If we find a light Higgs boson at the LHC, there should be many observable channels which we can exploit to measure the relevant parameters in the Higgs sector. We use the SFitter framework to map these measurements on the parameter space of a general weak-scale effective theory with a light Higgs state of mass 120 GeV. Our analysis benefits from the parameter determination tools and the error treatment used in new--physics searches, to study individual parameters and their error bars as well as parameter correlations.Comment: 45 pages, Journal version with comments from refere

    The Physics of the B Factories

    Get PDF

    Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

    No full text
    Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1–7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3–4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature
    corecore